Phosphofructokinase-1 (PFK1), the 'gatekeeper' of glycolysis, catalyses the committed step of the glycolytic pathway by converting fructose-6-phosphate to fructose-1,6-bisphosphate. Allosteric activation and inhibition of PFK1 by over ten metabolites and in response to hormonal signalling fine-tune glycolytic flux to meet energy requirements 1 . Mutations inhibiting PFK1 activity cause glycogen storage disease type VII, also known as Tarui disease 2 , and mice deficient in muscle PFK1 have decreased fat stores 3 . Additionally, PFK1 is proposed to have important roles in metabolic reprogramming in cancer 4,5 . Despite its critical role in glucose flux, the biologically relevant crystal structure of the mammalian PFK1 tetramer has not been determined. Here we report the first structures of the mammalian PFK1 tetramer, for the human platelet isoform (PFKP), in complex with ATP-Mg 21 and ADP at 3.1 and 3.4 Å , respectively. The structures reveal substantial conformational changes in the enzyme upon nucleotide hydrolysis as well as a unique tetramer interface. Mutations of residues in this interface can affect tetramer formation, enzyme catalysis and regulation, indicating the functional importance of the tetramer. With altered glycolytic flux being a hallmark of cancers 6 , these new structures allow a molecular understanding of the functional consequences of somatic PFK1 mutations identified in human cancers. We characterize three of these mutations and show they have distinct effects on allosteric regulation of PFKP activity and lactate production. The PFKP structural blueprint for somatic mutations as well as the catalytic site can guide therapeutic targeting of PFK1 activity to control dysregulated glycolysis in disease.
Phosphofructokinase-1 (PFK1), the 'gatekeeper' of glycolysis, catalyses the committed step of the glycolytic pathway by converting fructose-6-phosphate to fructose-1,6-bisphosphate. Allosteric activation and inhibition of PFK1 by over ten metabolites and in response to hormonal signalling fine-tune glycolytic flux to meet energy requirements 1 . Mutations inhibiting PFK1 activity cause glycogen storage disease type VII, also known as Tarui disease 2 , and mice deficient in muscle PFK1 have decreased fat stores 3 . Additionally, PFK1 is proposed to have important roles in metabolic reprogramming in cancer 4, 5 . Despite its critical role in glucose flux, the biologically relevant crystal structure of the mammalian PFK1 tetramer has not been determined. Here we report the first structures of the mammalian PFK1 tetramer, for the human platelet isoform (PFKP), in complex with ATP-Mg 21 and ADP at 3.1 and 3.4 Å , respectively. The structures reveal substantial conformational changes in the enzyme upon nucleotide hydrolysis as well as a unique tetramer interface. Mutations of residues in this interface can affect tetramer formation, enzyme catalysis and regulation, indicating the functional importance of the tetramer. With altered glycolytic flux being a hallmark of cancers 6 , these new structures allow a molecular understanding of the functional consequences of somatic PFK1 mutations identified in human cancers. We characterize three of these mutations and show they have distinct effects on allosteric regulation of PFKP activity and lactate production. The PFKP structural blueprint for somatic mutations as well as the catalytic site can guide therapeutic targeting of PFK1 activity to control dysregulated glycolysis in disease.
Previous attempts to obtain the structure of mammalian tetrameric PFK1 used native protein or recombinant protein generated in yeast or bacteria. A limitation of using native PFK1 is that most mammalian tissues express all three isoforms: muscle (PFKM), liver (PFKL) and platelet (PFKP) 7 . Although there are structures of PFK from prokaryotes [8] [9] [10] [11] and eukaryotes [12] [13] [14] , including dimeric rabbit PFKM expressed in Escherichia coli 12 , these structures provide limited information on the catalytic interface or the conformational changes with regulation of the tetrameic mammalian enzyme. To overcome current limitations with structural studies of human PFK1, we produced recombinant PFKP by using a baculovirus expression system. The recombinant enzyme, purified to homogeneity (Extended Data Fig. 1a ), is tetrameric as shown by transmission electron microscopy (TEM; Fig. 1a ). The activity and regulation of recombinant PFKP, including high cooperativity for fructose-6-phosphate (F6P), a high affinity for ATP-Mg 21 , and high sensitivity to ATP inhibition (Extended Data Fig. 1b, c) , was similar to previously reported mouse PFKP expressed in yeast 15 .
We determined the crystal structure of the PFKP tetramer in complex with ATP-Mg 21 at 3.1 Å resolution ( Fig. 1b-d and Extended Data Fig. 2 ). The atomic model has good agreement with the crystallographic data and the expected geometric parameters (Extended Data Table 1 ). The asymmetric unit contained two tetramers, and the eight protomers have essentially the same conformation (with r.m.s.d. of ,0.3 Å between any pair of them, Extended Data Fig. 3 ). The overall organizations of the two tetramers are slightly different, reflected in part by changes in the relative orientations of the two dimers (Extended Data Fig. 3 ).
Each PFKP tetramer measures 13.8 nm by 10.3 nm, similar in size and shape to what we calculated from TEM images ( Fig. 1a, b ). The tetramer is composed of a dimer of dimers, and the interface between the two dimers is relatively small, with a buried surface area of 700 Å 2 for each subunit (arrow labelled 't' in Fig. 1b , c). The two subunits of the dimer are arranged in an antiparallel orientation, confirming previous predictions 16 , with a buried surface area of 1,800 Å 2 for each subunit. The active site is located at the interface between the two subunits (arrow labelled 'c' in Fig. 1b, e ).
The structure of PFKP is likely to represent the active conformation of the enzyme. The crystal was prepared at pH 7, near physiological pH, and residues in the active site that are important for substrate binding and/or catalysis have similar conformations in PFKP as in other PFK structures (Fig. 1e ). The F6P substrate, as observed in the Saccharomyces cerevisiae PFK (ScPFK) structure 12 , can be readily accommodated in the PFKP active site for catalysis. The invariant substrate binding residues His208 and Arg210 from the second protomer of the dimer are located ,6 Å away from F6P, suggesting that a closure of this region of the active site may occur upon F6P binding and catalysis. PFKP contains only one ATP in each subunit bound to the active site, despite the presence of 10 mM ATP during crystallization and even though the allosteric adenine nucleotide-binding sites are functional (Extended Data Fig. 1b , c). We also observed the binding of two phosphate groups in each protomer at positions corresponding to the prokaryotic PFK effector sites (Extended Data Fig. 2c, d ). The enzyme activity, regulation and stability of PFK1 are controlled by binding phosphate or sulphate ions 17, 18 . PFKP displayed a loss of ATP inhibition in the presence of 10 mM sodium sulphate (Extended Data Fig. 2e ), suggesting that phosphate-binding and inhibitory site ATP-binding are mutually exclusive in the tetrameric structure.
We also determined the crystal structure of PFKP in complex with ADP at 3.4 Å resolution, at pH 7.5. The relatively low resolution of this structure precludes a detailed structural comparison with that of the ATP-Mg 21 complex. However, it is clear there is a dramatic change in the relative positions of the two domains in each protomer ( Fig. 2a) , and especially the overall structures of the dimer and tetramer ( Fig. 2b) . A rotation of ,12u is observed between the subdomains of the ADP complex protomer relatively to the ATP complex, leading to an 8 Å shift in the substrate binding domain relative to the nucleotide binding domain. An effect of this conformational change is to open the catalytic site ( Fig. 2c, d) , which may play a role in the release of products. The conformational changes observed between the ATP and ADP complexes of PFKP are different from those seen for the R-and T-states of bacterial PFK (Extended Data Fig. 4) 8, 19 .
We tested the importance of hydrophobic and electrostatic interactions at the tetramer interface for enzyme activity (Fig. 3a) . Most residues at the interface are hydrophobic. Tyr645 and Phe649 from the two subunits form a p-stack of four aromatic side chains in the interface, with Phe649 in the middle (Fig. 3a) . Despite the overall similarities in organization between the PFKP tetramer to that of ScPFK 12 , there are significant differences in the tetramer interface between the two enzymes (Extended Data Fig. 5 ). Phe649, which is evolutionarily conserved in metazoans but not in yeasts, is a leucine residue in ScPFK a-subunit. However, this Leu residue has a completely different local environment in ScPFK compared with Phe649 in PFKP. We generated recombinant PFKP with Phe649 mutated to Leu (Extended Data Fig. 6a ) to test whether Phe649 is required for tetramer formation. Previous studies showed that PFK1 assembles into tetramers in a concentration-and ligand-dependent manner, with allosteric activators favouring the formation of tetramers and allosteric inhibitors favouring the formation of dimers [20] [21] [22] . In a buffer containing ADP, ATP and F6P, TEM showed that wild-type (WT) PFKP particles had the dimensions and appearance of tetramers ( Fig. 3b, c) . In contrast, PFKP-F649L particles were the same width but half the length of WT, consistent with dimer formation along the catalytic interface (Fig. 3b , c and Extended Data Fig. 6b ). We compared the PFKP-F649L particles with those induced by the inhibitor citrate, which cause PFKM to form dimers 23 . In a buffer containing 1 mM citrate, we saw two sizes of particles with WT PFKP: one with dimensions of tetramers and the other with dimensions of dimers along the catalytic interface (Fig. 3b , c and Extended Data Fig. 6c ), further confirming dimer formation by PFKP-F649L. The catalytic activity of PFKP-F649L was reduced 98% (Extended Data Fig. 6d ) compared with WT enzyme, indicating that tetramer formation is necessary for PFK1 activity.
The structures suggest that an electrostatic interaction at the tetramer interface between Arg613 of one subunit and Glu657 of the adjacent subunit ( Fig. 3a ) may be important for enzyme function. This salt bridge was only observed in the ATP-bound structure but not in the ADP-bound PFKP structure or dimeric rabbit PFKM structures 12 , suggesting that it may contribute to maintaining an active form of the mammalian tetramer. PFKP-E657A had reduced affinity of ,4.5 mM for F6P, compared with ,0.8 mM in WT, and an approximately twofold decrease in maximum activity ( Fig. 3d , Extended Data Fig. 6a and Extended Data Table 2 ). Our data indicate that hydrophobic interactions are essential for the formation of tetramers while electrostatic interactions are required for optimal enzyme activity.
The structure of PFKP provides a foundation for understanding the functional effects of somatic PFK1 mutations identified in cancers. Cancer cells rely on aerobic glycolysis to provide energy and cellular building blocks required to support rapid proliferation 6 . PFK1 activity is increased in cancer cell lines and primary tumour tisues 24 and expression of PFKP is upregulated in breast 25 and liver 26 cancers. The effect of somatic mutations in PFK1 on metabolic adaptation has not been reported. We mapped the 44 reported somatic mutations 
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in cancers 27 that were not associated with single nucleotide polymorphisms 28 onto the structure of PFKP ( Fig. 4a and Extended Data Table 3 ). Analysis by Mutation Assessor 29 predicted that 28 of these mutations would alter enzyme activity. We selected three identified somatic mutations for biochemical analysis (Extended Data Fig.7 ). Arg48 interacts with a bound phosphate ion in the structure (Fig. 4b) , and the R48C mutant had reduced citrate inhibition, shifting E 50 citrate from 0.4 mM for WT to greater than 4 mM ( Fig. 4d ) but did not markedly change effects of ATP and F6P (Fig. 4e , f and Extended Data Table 2 ). Analogous mutations in PFKM have been described in Tarui disease 20, 30 . These data indicate that Arg48 is located in the citrate-binding site, which is occupied by the phosphate ion in the current structure 30 . A serine substitution for Asn426, located close to the catalytic interface, is predicted to disrupt interactions with the backbone carbonyls of Gln472, Gly473 and Gly474 and the main-chain amide of Ile476, which are involved in positioning a loop at the catalytic interface (Fig. 4c ). The N426S mutant partly relieves ATP inhibition, shifting EC 50 ATP from ,1 mM to greater than 3 mM (Fig. 4e) . Located across the catalytic interface from Asn426, Asp564 forms an electrostatic interaction with Arg319 (Fig. 4b) . The D564N mutant had decreased maximum velocity and affinity for F6P ( Fig. 4f and Extended Data Table 2 ). We also stably expressed PFKP WT and mutants tagged with green fluorescent protein (GFP) in MTLn3 rat mammary adenocarcinoma cells (Extended Data Fig. 7b ). In cell lysates, PFK1 activity was greater with expression of WT, N426S and D564N but not R48C compared with untransfected or GFP controls (Extended Data Fig.7c ). Lactic-acid excretion was also greater with cells expressing WT and N426S but significantly less with D564N compared with GFP controls (Fig. 4g ). Inhibition of glycolytic flux by loss of function mutations, such as D564N, may confer a selective advantage for cancer cell growth and metastasis by redirecting carbon flow through the pentose phosphate pathway, similar to that observed by glycosylation-dependent PFK1 inhibition 4 . However, relief of inhibition by allosteric regulators had no effect on lactate 
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production in the glutamine-free cell-culture conditions we used. This finding could reflect the ability of PFK1 to dynamically alter metabolic states by integrating multiple signals. Additionally, the functional significance of selective PFKP mutations will depend on the mutational signature of the respective cancer in which they occur as well as the relative expression of other PFK1 isoforms.
In addition to cancer, aberrant glycolytic flux is increasingly recognized as contributing to several other diseases such as obesity, diabetes and Tarui disease. The biologically relevant tetrameric structures of the PFKP provide information on the catalytic interface and conformational changes upon ATP hydrolysis that contributes to a mechanistic understanding of the functional impact of disease-associated mutations. Additionally, these new structural insights will enable rational drug design for therapeutic development.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
No statistical methods were used to predetermine sample size. Cloning, expression and purification of recombinant human PFKP. Homo sapiens PFKP complementary DNA (cDNA) (NM_002627.4) encoding the 784amino-acid isoform 1 was cloned into the pFastBac HTa vector and baculovirus was generated using the Bac-to-Bac Expression system (Invitrogen) according to the manufacturer's protocols. Two billion sf21 or Hi5 cells were used to express PFKP at a multiplicity of infection of 1 for 48 h. Cell pellets were resuspended in lysis buffer (20 mM tris(hydroxymethyl)aminomethane (Tris-HCl; pH 7.5); 50 mM potassium phosphate; 1 mM 2-mercaptoethanol; 10% glycerol; 10 mM imidazole; cOmplete Protease Inhibitor Cocktail tablet (Roche)) and lysed with 15 passes of a dounce homogenizer. Cell debris was removed by centrifugation and the pellet discarded. The supernatant was incubated with Talon resin (Clontech), washed with 20 bed volumes of lysis buffer and eluted with a minimal volume of elution buffer (lysis buffer with 100 mM imidazole). Protein was concentrated using an Amicon Ultracel-30K Centrifugal Filter Unit (Milipore) and buffer exchanged into FPLC buffer (20 mM HEPES, pH 7.5, 100 mM KCl, 1 mM TCEP, 1 mM ATP, 1 mM MgCl 2 , and 5% glycerol). PFKP was passed over a Superose 6 10/300 GL column (GE Healthcare) and the peak corresponding to the tetrameric fraction collected. Buffer was exchanged to crystallization buffer (20 mM HEPES, pH 7.5, 100 mM KC, 1 mM TCEP, 10 mM MgCl 2 , and 5% glycerol) containing either 10 mM ADP or 10 mM ATP using an Amicon Ultracel-30K Centrifugal Filter Unit and recombinant PFKP concentrated to .5 mg ml 21 . Protein was stored at 4 uC. Recombinant PFKP was tested for activity and allosteric regulation before crystallization. PFK1 activity assays. Activity assays for PFK1 were preformed using an auxiliary enzyme assay 31 . Kinetic studies were performed in 200 ml reaction containing 50 mM HEPES pH 7.4, 100 mM KCl, 10 mM MgCl 2 , 0.15 mM NADH, 0.675 units ml 21 aldolase, 5 units ml 21 triosephosphate isomerase and 2 units ml 21 glycerol phosphate dehydrogenase. ATP and F6P were used as indicated. Auxiliary enzymes were de-salted using an Amicon Ultracel-10K Centrifugal Filter Unit before use. The concentration of PFKP was normalized and samples diluted as a 103 stock in 10% glycerol, 20 mM Tris-HCl (pH 7.5) and 1 mM DTT immediately before the assay. The temperature was equilibrated to 25 uC for 10 min before initiating the reaction with the addition of PFKP. The absorbance at 340 nm was measured using a SpectraMax M5 microplate reader (Molecular Devices). Kinetic parameters were generated by linear regression analysis of the Hill equation using Prism (GraphPad Software) and are the average of a minimum of three measurements from two independent preparations of protein (R 2 . 0.95 for all analyses). An unpaired t-test with equal variance was used to compare the activity of WT and F649L PFKP. One unit (U) of activity is defined as the amount of enzyme that catalyses the formation of 1 mmol of fructose-1,6-bisphosphate per minute at 25 uC. Data on the effect of sulphate on PFK1 activity were obtained in the presence of 10 mM sodium sulphate or 10 mM sodium chloride as a control. Transmission electron microscopy. Twenty microlitres of 25 mg ml 21 PFKP was applied to glow-discharged carbon-coated grids and stained with 2% (w/v) uranyl acetate. Grids were examined and photographed with a JEOL 100CX II. For estimation of size of PFKP dimers and tetramers, the length and width of individual particles from TEM images were measured using FIJI ImageJ software 32 . The average length and width 6 s.d. are reported. For experiments analysing the shape and size of PFKP for crystallography studies, the protein was diluted in TEM buffer (20 mM HEPES, pH 7.5, 100 mM KCl, 1 mM DTT, 1 mM ATP, 1 mM MgCl 2 and 5% glycerol). For experiments analysing the oligomeric state of the enzyme in the presence of activators, WT and F649L PFKP were diluted in TEM buffer containing 3 mM ADP, 3 mM ATP and 8 mM F6P. For experiments analysing the oligomeric state of the enzyme in the presence of inhibitors, PFKP was diluted in TEM buffer containing 1 mM citrate. Crystallization and structure determination. PFKP was crystallized in two different complexes of ADP and ATP-Mg 21 by a microbatch method at 18 uC. For the ADP complex, 2 ml of protein solution containing PFKP (6.35 mg ml 21 ) was mixed with 1 ml of the precipitant solution consisting of 200 mM potassium sodium tartrate tetrahydrate, pH 7.4, and 20% (w/v) PEG 3350. The same protein buffer was used for growing the crystals of the PFKP in complex with ATP and Mg 21 . The crystals were obtained using microbatch method and the precipitant solution comprising 200 mM potassium thiocyanate, pH 7, and 20% (w/v) PEG 3350. All crystals were cryoprotected by addition of 20% (v/v) ethylene glycol in the respective mother liquor and flash-frozen in liquid nitrogen for data collection at 100 K.
Crystals of the PFKP complexes both belong to space group P2 1 . However, the crystallographic asymmetric unit of the ADP-bound form contains four subunits of PFKP that are assembled as one tetramer, whereas that of ATP-Mg 21 form contains two tetramers. A single-wavelength native data set to resolution 3.1 Å was collected at the X4C beamline of the National Synchrotron Light Source. The diffraction images were processed with the HKL package 33 . The structure of PFK from rabbit skeletal muscle (PDB accession number 3O8L) 12 was used to determine the ATP-Mg 21 structure of PFKP using the molecular replacement method, with the program MolRep 34 . Only a monomeric model of PFK from rabbit skeletal muscle resulted in a solution, which led to structure determination of the ATP-bound PFKP structure. The remainder of the PFKP model was built manually with the program XtalView 35 . The structure refinement was performed with CNS 36 . A similar methodology was used for data collection and processing of the ADP-bound structure of PFKP, the crystal of which diffracted to 3.4 Å at the X4C beamline of the National Synchrotron Light Source. The ADP-bound structure was subsequently determined using a monomeric model of the ATP-bound complex of PFKP, with the program MolRep 34 followed by structure refinement by CNS 36 . The data processing and refinement statistics are summarized in Extended Data Table 1 . The Ramachandran plots suggest that 88.1% and 81.9% of residues in ATP-bound complex and ADP-bound complex of PFKP are in most favoured regions, and there is no residue in disallowed regions, respectively. The trajectory between the ATP-Mg 21 -bound and the ADP-bound structures was generated using UCSF Chimera 37 . The structures were aligned with Matchmaker tool and the trajectory calculated with the Morph Conformation tool. Selection of cancer mutations and generation of point mutants. Somatic mutations identified in human cancers were selected from the COSMIC database 27 and known single nucleotide polymorphisms were disregarded 28 . The mutations were modelled onto the structure of PFKP and selected for further analysis. Point mutants at the tetramer interface, F649L and E657A, and cancer mutants, R48C N426S, and D564N, were generated by using a commercially available site-directed mutagenesis kit (QuikChange Lightning, Aligent). DNA primers were designed using the online primer design tool (http://www.genomics.agilent. com/primerDesignProgram.jsp) and purchased from Elim Biopharmaceuticals. Analysis of cells expressing PFKP. A mammalian PFKP expression construct was generated by PCR amplification and the cDNA inserted into the multiple cloning site of pEGFP-N1 using the restriction enzymes XhoI and BamHI. Cancer mutations were generated by site-directed mutagenesis as described above. Constructs were expressed by transfecting MTLn3 rat mammary adenocarcinoma cells 38 using FugeneHD (Promega) transfection reagent. One-day post-transfection cells were re-plated into 100 mm dishes and 800 mg ml 21 G418 was added to select for transfected cells. After 1 week of selection, fluorescence-activated cell sorting was used to sort cells expressing GFP. For metabolic assays, cells were seeded into a six-well plate at a density of 3 3 10 5 cells per well. One day after replating, cells were washed twice in serum-and glutamine-free media, and cells were incubated for 2 h in 1 ml of the same media. Fifty microlitres of the media were collected in triplicate and the amount of lactic acid in the media measured using an enzyme-linked assay 39 . One hundred microlitres of reagent A (300 mM hydrazine; 200 mM glycine, pH 9.5; 20 mM b-nicotinamide adenine dinucleotide) and 50 ml of reagent B (200 U ml 21 L-lactate dehydrogenase from rabbit muscle (Sigma Aldrich) were added to each well and incubated for 1 h at 22 uC. The absorbance at 340 nm was measured and the amount of lactate was determined from a standard curve. Cells were lysed in buffer (10 mM potassium phosphate, pH 7.5; 0.1% Triton X-100; cOmplete Protease Inhibitor Cocktail tablet (Roche)), cellular debris removed by centrifugation and the protein concentration determined by the Bradford method. Lactic-acid levels in the media were normalized to protein concentration. PFK1 activity assays were performed on the lysate as previously described 40 . Enzyme-linked PFK1 activity assays were performed on 10 mg of total cell lysate as described above with the exception that 10 mM ammonium sulphate was added to the assay mixture and the auxiliary enzymes were not desalted. Levels of PFKP expression were determined by immunoblotting using rabbit anti-GFP (Invitrogen A-11122, 1DB-001-0000868907) and mouse antiactin clone C4 (ED Millipore MAB1501, 1DB-001-0000850281) antibodies. Two-sided paired t-tests were used to determine statistical significance. c-phosphate of the nucleotide, which was unambiguously modelled as Mg 21 ion. An extended but weaker electron density is also observed near the c-phosphate of the nucleotide, which is surrounded by three backbone carbonyls of strictly conserved Ser32, Gly34 and Gly172. This electron density was modelled as a second metal ion, although it may belong to a water molecule. c, d, Structure of the two inorganic phosphate-binding sites in PFKP. e, Plot of concentration of ATP versus relative enzymatic activity of PFKP in the presence (black triangles) and absence (grey circles) of 10 mM sodium sulphate.
